Study history
Studies started at Oslo University Hospital with involvement from Department of Clinical Cancer Research (Seksjon for utprøvende kreftbehandling)
| STUDIES STARTED IN 2021: | DIAGNOSIS |
SPONSOR |
PHASE | CLINICAL TRIALS |
| CORINTH: Phase 1B/II Trial of checkpointinhibitor(Pemborlizumab and anti PD-1 antibody) plus standard IMRT in HPV induced stage III Squamous Cell Carsinoma (SCC) of Anus | Anal | Cardiff university | Phase I/II | |
| CA017-078: A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-In | Bladder | BMS | Phase III | |
| MK7339-012: A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Adva | Lung | MSD | Phase III | |
| CA022-001: En fase 1 / 2a studie av monoklonalt antistoff BMS-986218 som monoterapi og i kombinasjon med Nivolumab hos pasienter med avanserte solide tumorer. | Melanoma | BMS | Phase I/II | |
| V937-013: A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participant with Advanced/Metastatic Solid Tumors | Multiple diagnoses | MSD | Phase I/II | |
| NAVIGATE: En basket-studie i fase 2 av den orale TRK-hemmeren larotrectinib hos pasienter med NTRK-fusjonspositive tumorer | Bayer | Phase II | ||
| EPIK-B3: A Phase II, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinsi | Mamma | Novartis | Phase III | |
| KO_TIP_007: The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First | Head and neck | KURA Oncology | Phase III | |
| MK1454-002: A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination with IV Pembrolizumab vs IV Pembrolizumab Monotherapy | Head and neck | MSD | Phase II | |
| INCB-54828-302 / Fight-302: A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarc | Cholangiocarcinom | Incyte Corporation | Phase III | |
| Re-RAD-I: External beam radiotherapy for pelvic recurrences in rectal cancer patients previously treated with radiotherapy | Colorectal | Phase II | ||
| CANOPY-1: A randomized, double-A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or me | Lung | Novartis | Phase III | |
| UVEA-Brig: Use via expanded access to brigatinib | Lung | Takeda Pharmaceuticals International | Reg | |
| ORCHARD: A Biomarker-Directed Phase 2 Platform Study in Patients with AdvancedA Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy | Lung | Astra Zeneca | Phase II | |
| BLU-667-2303: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer | Lung | Blueprint Medicinese Corporation | Phase III | |
| GSK-ZEAL-1: NSCLC 1 linje beh med PARP-hemmer og pembrolizumab, fase 3A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose D | Lung | GSK | Phase III | |
| CLXH254C12201: En studie for å vurdere effekt og sikkerhet av flere kombinasjonsbehandlinger med LXH254 hos pasienter med tidligere behandlet ikke-operabel eller metastatisk melanom med BRAFV600 eller NRAS mutasjon | Melanoma | Novartis | Phase II | |
| MCLA-128-CL01: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors | Multiple diagnoses | Merus NV | Phase I/II | |
| TALAPRO-2: A phase 3, randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer | Prostata | Pfizer | Phase III | |
| TENDU-101: A First-in-Man, Open-label, Single center, Dose-selection Study of Safety and Effect of Different Doses of TENDU Vaccine, a Therapeutic Peptide Conjugate Vaccine, in Patients with Relapse after Primary Radical Prostatectomy | Prostata | Ultimovacs | Phase I | |
| rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma | Sarcoma | Euro Ewing Consortium | Phase II/III | |
| STS: Sequential neoadjuvant ifosfamide and doxorubicin in localized high-grade soft tissue sarcoma of extremities and trunk wall | Sarcoma | Oslo university hospital | Phase II | |
| NEC: Kliniske, radiologiske og molekylære karakteristika hos pasienter som behandles for gastroenteropankreatisk nevroendokrine svulster | Esophagus | Oslo university hospital | Obs | |
| NeoRes 2: Randomized clinical trial comparing the timing of resective surgery after neoadjuvant chemoradiotherapy in cancer of the esophagus or gastric cardia |
Esophagus | Scandinavian Esophageal and Gastric Cancer Group | Phase II | |
| NEEDS: NEoadjuvant Chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed | Esophagus | Karolinska university hospital | Phase IV | |
| STUDIES STARTED IN 2020: | DIAGNOSIS | SPONSOR | PHASE | CLINICAL TRIALS |
| CA209-8HW: A Phase 2 Clinical Trial of Nivolumab Monotherapy in Previously Treated Recurrent or Metastatic Microsatellite Instability High (MSI-H) Colorectal Cancer | Colorectal | BMS | Phase II | |
| BM7PE: A phase I/II study with BM7PE immnotoxin in colorectal cancer patients with metastatic disease who are refractory to or with intorerance to last line of standard chemotherapy | Colorectal | Oslo university hospital | Phase I/II | |
| Bortem-17: Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to Temozolomide phase 1B/II study | CNS | Haukeland university hospital | Phase I/II | |
| Tungespacerstudien: Pasientrapporterte utfall ved bruk av tungespacer under strålebehandling av kreft i munnhule eller bihule | Head and neck | Oslo university hospital | Phase II | |
| INDUCE-3: A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment | Head and neck | GSK | Phase II | |
| EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE) | Esophagus | EORTC | Phase II | |
| MK3475-867: A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Can | Lung | MSD | Phase III | |
| DART: Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients | Lung | Oslo university hospital | Phase II | |
| NIPU: Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma | Lung | Oslo university hospital | Phase II | |
| EORTC 1825-LCG: Acitivity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor | Lung | EORTC | Phase II | |
| BELINDA: Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial | Lymphoma | Novartis | Phase III | |
| AERN: Abscopal Effect of Radiotherapy and Nivolumab in anti-PD-1 Pretreated Relapsed or Refractory Hodgkin Lymphoma: An International Multicenter Phase II Trial | Lymphoma | University of Cologne | Phase II | |
| Polar Bear: R-mini-CHOP versus R-mini-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffus large B-cell lymphoma, =80 years, or frail =75 years - an open label randomized Nordic Lymphoma group phase III trial - NLG-LBC7 | Lymphoma | Lung university hospital | Phase III | |
| UV1-202: A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma | Melanoma | Ultimovacs | Phase II | |
| CA209-76K: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma | Melanoma | MSD | Phase III | |
| V937-011: A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants with Advanced/Metastatic Melanoma | Melanoma | MSD | Phase II | |
| ImPRESS: Imaging Perfusion Restrictions from Extracellular Solid Stress | Multiple diagnoses | Oslo university hospital | Phase II | |
| Off-label study: Off-label use of anti-cancer drugs in Norway | Multiple diagnoses | Oslo university hospital | Obs | |
| PACTO: A multinational, randomized, phase ii study of the combination of nab-paclitaxel and gemcitabine a multinational, randomized, phase ii study of the combination of nab-paclitaxel and gemcitabine with or without il-6r inhibitor, tocilizumab, as first-line treatment | Pancreas | Herlev and Gent hospital | Phase II | |
| STUDIES STARTED IN 2019: | DIAGNOSIS | SPONSOR | PHASE | CLINICAL TRIALS |
| INCMGA 0012-202: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | Anal | Incyte corporation | Phase II | |
| PCI-A203-18: A multi-centre randomised open-label Phase II Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-induced Photochemical Internalisation (PCI) of Gemcitabine followed by Gemcitabine/Cisplatin Chemotherapy versus Gemcitabine/ Cisplatin alone | Cholangiocarcinom | PCI Biotech | Phase II | |
| ICO-CC-005: An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of [6R] 5,10-Methylene Tetrahydrofolate (Modufolin®) in Combination with a Fixed Dose of 5-Fluorouracil (5-FU) alone or together with a Fixed Dose of Oxaliplatin or Irinotecan in Patients with Stage IV Colorectal Cancer | Colorectal | Isofol | Phase I/II | |
| PROTEOS: Protein intake in patients with colorectal or lung cancer during first line treatment with chemo(radio)- or immunotherapy when receiving a low volume, energy dense and high protein oral nutritional supplement: a randomised, controlled study | Colorectal | Nutrica Research | Phase IV | |
| METIMMOX: Colorectal cancer metastasis - Shaping anti-tumor immunity by Oxaliplatin | Colorectal | Akershus university hospital | Phase II | |
| DIRECT: (DIsulfiram REsponse as add-on to ChemoTherapy in recurrent) Glioblastoma: A randomized controlled trial | CNS | Sahlgrenska university hospital | Phase II | |
| CA224-060: A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Ad | Esophagus | BMS | Phase II | |
| INTENSE: Irinotecan-basert triplett (FOLFOXIRI) kjemoterapi som cellegift behandling før og etter operasjon for kreft i magesekken og overgang mellom spiserør og magesekken (INTENSE studie) | Esophagus | Skåne university hospital | Phase II | |
| MK3475-630: A phase 3, randomized, double-blind, placebo-controlled study to evaluate Pembrolizumab versus placebo as a adjuvant therapy following surgery and radiation in participants with high-risk locally advanced cutaneous squamous cell carcinoma | Head and neck | MSD | Phase III | |
| MK3475-937: A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ab |
Liver/bile duct | MSD | Phase III | |
| FIOL: First-line treatment with osimertinib in EGFR-mutated non-small cell lung cancer, coupled to extensive translational studies (FIOL) | Lung | Vestre Viken | Phase II | |
| ASTEROID: Ablative stereotactic Radiotherapy with Durvalumab (MEDI4736). An open label randomized phase 2 trial with durvalumab following stereotactc Body radiotherapy (SBRT) in patient with T1-2N0M0 Non-small Cell Lung Cancer (NSCLC). | Lung | Sahlgrenska university hospital | Phase II | |
| NARLAL 2: Novel Approach to Radio Therapy in Locally Advanced Lung Cancer - Heterogeneous FDG-guided dose escalation with concomitant Navelbine | Lung | Odense university hospital | Phase III | |
| CANOPY-A: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as aduvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected ( | Lung | Novartis | Phase III | |
| ELARA: A phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma | Lymphoma | Novartis | Phase III | |
| Lymrit-37-01: A phase I/II study of lutetium-lilotomab satetraxetan antibody-radionuclide-conjugate for treatment of relapsed non-Hodkin lymphoma | Lymphoma | Nordic Nanosector | Phase I/II | |
| ONCOS C824: A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients with Advanced or Unresectable Melanoma Progressing after PD1 Blockade | Melanoma | Targovac | Phase I | |
| Debio 1347-201: A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3 | Multiple diagnoses | Debiopharm | Phase II | |
| MX39795 CUPISCO: A phase II trial comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with CUP | Origo inserta | Roche | Phase II | |
| D6070C00005: A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma | Pancreas | Astra Zeneca | Phase I/II | |
| STORM: A randomized phase II trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) | Prostata | Gent university hospital | Phase II | |
| SACRO: S+B10Acral Chordoma: a Randomized & Observational study on surgery versus definitive radiation therapy in primary localized disease | Sarcoma | Italian Sarcoma Group | Obs | |
| INTRIGUE: A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-In | Sarcoma | Deciphera Pharma ceuticals | Phase III | |
| FAKT: Physically Active During Cancer Treatment | Stomach | St. Olavs Hospital | Other | |
| STUDIES STARTED IN 2018: | DIAGNOSIS | SPONSOR | PHASE | CLINICAL TRIALS |
| ARRAY-818-302: Clonal evolution and prediction of response to (ARRAY) targeted therapy in patients with BRAF-mutant colorectal cancer. | Colorectal | Array Biopharma | Phase III | |
| TCR-CRC-001: T cell receptor based therapy of metastatic colorectal cancer with mRNA-engineered T cells targeting transforming growth factor beta receptor type II (TGFßII) | Colorectal | Oslo university hospital | Phase I | |
| EORTC 1709: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma | CNS | EORTC | Phase III | |
| DEN-STEM: Open label randomized phase II/III trial of dendritic cell immunotherapy against cancer stem cells in glioblastoma patients receiving standard therapy | CNS | Oslo university hospital | Phase II/III | |
| CA209-9M9 (INEC): Safety and feasibility of irradiation and nivolumab in esophageal cancer | Esophagus | Oslo university hospital | Phase I/II | |
| MK3475-629: A Phase 2, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) | Head and neck | MSD | Phase II | |
| DAHANCA30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC | Head and neck | DAHANCA | Phase III | |
| NTCP: Development and validation of NTCP (normal tissue complication probability) models for head and neck cancer | Head and neck | Haukland university hospital | Other | |
| BGBC008: A Phase II, Multi-Centre Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung | Lung | BerGenBio | Phase II | |
| ICI: The new check point inhibitors – identification of predictive biomarkers in lung cancer | Lung | Oslo university hospital | Obs. | |
| COM-IT 1: Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PDL-1 blockade in locally advanced / advanced NSCLC | Lung | Oslo university hospital | Phase II | |
| Achiles: A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small-cell lung cancer | Lung | NTNU | Phase II | |
| HD-21: Treatment optimization trail in the first-line treatment of advanced stage Hodkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD | Lymfoma | University of Cologne | Phase III | |
| P(R)EBEN: A Phase I/II study of the combination of pixantrone, etopside, bendamustine and, in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodkin lymphomas of B- or T-cell phenotype - The P(R)EBEN study | Lymfoma | Århus university hospital | Phase I/II | |
| Bio-CHIC: BIOmarker driven dose intensified CHemoImmunotherapy with early CNS prophylaxis | Lymfoma | Helsinski university hospital | Phase II | |
| MATRix/IELSG43: High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial | Lymfoma | University of Stuttgard | Phase III | |
| ENRICH: Randomised, open label study of rituximab / Ibrutinib vs Rituximab / Chemotherapy in older patients with untreated mantle cell lymphoma | Lymfoma | Plymouth Hospitals NHS Trust | Phase II/III | |
| VALERIA: Venetolax, lenalidomide and rituximab in patients with relapsed / refractory mantle cell lymphoma | Lymfoma | Nordic Lymphoma Group | Phase I/II | |
| Archer-1: A phase 1b open-label study of Betalutin in combination with rituximab in patients with relapsed/refractory follicular lymphoma | Lymfoma | Nordic Nanovector | Phase I/II | |
| ICON CA209-9FN: A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone reseptor positive breast cancer | Mamma | Oslo university hospital | Phase II | NCT03409198 |
| EMIT-1: Establishment of Molecular profiling for Individual clinical routine Treatment decision in Early Breast Cancer (EMITEBC-1) | Mamma | Oslo university hospital | Phase II | |
| OPTIMA: Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis | Mamma | University College London | Phase III | |
| COMBI-I: A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma | Melanoma | Novatis | Phase III | |
| CLXS196X2101: A Phase I, multi-center, open-label, study of LXS196, an oral protein kinase C inhibitor, in patients with metastatic uveal melanoma | Melanoma | Novatis | Phase I | |
| COMBI-APlus: Open-label, phase IIIb study of dabrafenib in COMBInation with trametinib in the Adjuvant treatment of stage III BRAF V600 mutation-positive melanoma after complete resection to evaluate the impact on pyrexia related outcomes of an adapted pyrexia AE-man | Melanoma | Novatis | Phase III | |
| CA224-047: A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma | Melanoma | BMS | Phase II/III | |
| CA017-003: A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors | Multiple diagnoses | BMS | Phase I/II | |
| MK3475-587: A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. | Multiple diagnoses | MSD | Phase III |
Updated 12 may 2021